The WNBA has announced a new multi-year partnership with Opill, the manufacturer of the first over-the-counter daily birth control pill in the US.
The partnership will focus on the league’s efforts this season to bring attention to civic engagement and reproductive health advocacy.
Opill will serve as an associate partner of the upcoming WNBA Draft, with the public debut of the partnership scheduled for next week.
Both organizations plan to jointly host events on college campuses across the US to celebrate change-makers and raise awareness about the new OTC contraceptive option.
“At the WNBA, we are committed to addressing issues that matter to the players, and expanding access to reproductive healthcare is one of those key issues,” WNBA Chief Growth Officer Colie Edison stated.
“It’s great to be working with a partner whose values align and authentically integrates into the health equity work our players are dedicated to,” she said.
“Opill is changing the game in reproductive health, just like the WNBA’s game-changing role in sports and pop culture,” Leila Bahbah, Perrigo U.S. Women’s Health Brand Lead stated.
